{"id":"https://openalex.org/W2946947282","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.e14232","title":"Collagen affinity improves efficacy and safety of antibody and cytokine cancer immunotherapy.","display_name":"Collagen affinity improves efficacy and safety of antibody and cytokine cancer immunotherapy.","publication_year":2019,"publication_date":"2019-05-20","ids":{"openalex":"https://openalex.org/W2946947282","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.e14232","mag":"2946947282"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2019.37.15_suppl.e14232","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.e14232","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.e14232","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5010360763","display_name":"Ako Ishihara","orcid":"https://orcid.org/0000-0002-7426-5736","observed_orcids":["https://orcid.org/0000-0002-7426-5736"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ako Ishihara","raw_affiliation_strings":["The University of Chicago, Chicago, IL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Chicago, Chicago, IL;","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084172811","display_name":"Jun Ishihara","orcid":"https://orcid.org/0000-0002-9083-9859","observed_orcids":["https://orcid.org/0000-0002-9083-9859"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jun Ishihara","raw_affiliation_strings":["University of Chicago, Chicago, IL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago, Chicago, IL;","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031517705","display_name":"Jeffrey A. Hubbell","orcid":"https://orcid.org/0000-0003-0276-5456","observed_orcids":["https://orcid.org/0000-0003-0276-5456"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey A Hubbell","raw_affiliation_strings":["The University of Chicago, Chicago, IL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Chicago, Chicago, IL;","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5088767177","display_name":"Melody A. Swartz","orcid":"https://orcid.org/0000-0001-5484-1903","observed_orcids":["https://orcid.org/0000-0001-5484-1903"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Melody A Swartz","raw_affiliation_strings":["The University of Chicago, Chicago, IL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Chicago, Chicago, IL;","institution_ids":["https://openalex.org/I40347166"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I40347166"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"37","issue":"15_suppl","first_page":"e14232","last_page":"e14232"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0032999999821186066,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0026000000070780516,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/collagen-binding-domain","display_name":"collagen-binding domain","score":0.8299999833106995},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.675000011920929},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9729999899864197},{"id":"https://openalex.org/keywords/anti-ctla-4","display_name":"anti-CTLA-4","score":0.8889999985694885},{"id":"https://openalex.org/keywords/pd-l1-inhibitors","display_name":"PD-L1 inhibitors","score":0.9940000176429749},{"id":"https://openalex.org/keywords/interleukin-2","display_name":"interleukin-2","score":0.9879999756813049},{"id":"https://openalex.org/keywords/tumor-targeting","display_name":"tumor targeting","score":0.6949999928474426},{"id":"https://openalex.org/keywords/hepatotoxicity","display_name":"hepatotoxicity","score":0.8360000252723694},{"id":"https://openalex.org/keywords/capillary-leak","display_name":"capillary leak syndrome","score":0.9470000267028809},{"id":"https://openalex.org/keywords/pulmonary-edema","display_name":"pulmonary edema","score":0.8849999904632568},{"id":"https://openalex.org/keywords/cd8-tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating CD8+ T cells","score":0.8849999904632568},{"id":"https://openalex.org/keywords/regulatory-t-cells","display_name":"regulatory T cells","score":0.7699999809265137},{"id":"https://openalex.org/keywords/b16f10-melanoma","display_name":"B16F10 melanoma","score":0.9789999723434448},{"id":"https://openalex.org/keywords/ct26-cells","display_name":"CT26 cells","score":0.9639999866485596}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8310328722000122},{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.6323705911636353},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5665907263755798},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.56122887134552},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5032932162284851},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.4775013327598572},{"id":"https://openalex.org/C2780674031","wikidata":"https://www.wikidata.org/wiki/Q2012719","display_name":"Cancer immunotherapy","level":4,"score":0.4722318649291992},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.46075233817100525},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.42497706413269043},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3915093243122101},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2677745223045349}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2019.37.15_suppl.e14232","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.e14232","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.e14232","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.8600000143051147,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4255576633","https://openalex.org/W2911232985","https://openalex.org/W2939112943","https://openalex.org/W4409629075","https://openalex.org/W2944739527","https://openalex.org/W4386797105","https://openalex.org/W3016092372","https://openalex.org/W3212852015","https://openalex.org/W4388871182","https://openalex.org/W2887641559"],"abstract_inverted_index":{"e14232":[0],"Background:":[1],"Cancer":[2],"immunotherapy":[3],"with":[4,21,234,243,255,279,288],"immune":[5,29],"checkpoint":[6],"inhibitors":[7],"(CPI)":[8],"and":[9,27,48,133,145,166,178,195,202,205,236,277,291],"interleukin":[10],"(IL)-2":[11],"have":[12,171],"demonstrated":[13],"clinical":[14],"antitumor":[15],"efficacy":[16,292],"but":[17],"is":[18],"frequently":[19],"accompanied":[20],"severe":[22],"side-effects":[23,170],"caused":[24],"by":[25,37],"excessive":[26],"systemic":[28,126,152],"system":[30],"activation.":[31],"Methods:":[32],"We":[33,102],"addressed":[34],"this":[35],"need":[36],"targeting":[38,286],"both":[39,129,203],"the":[40,49,57,63,72,84,95,98,125,143,156,175,214,244,256,264],"CPI":[41,137,235,276],"antibodies":[42],"anti-CTLA4":[43],"(aCTLA4)":[44],"+":[45],"anti-PD-L1":[46],"(aPD-L1)":[47],"cytokine":[50,153],"IL-2":[51,161,237],"to":[52,65,90,94,136,160,185,220,272,294],"tumors":[53,112,239],"via":[54],"conjugation":[55,121],"(for":[56,62],"antibodies)":[58],"or":[59,122],"recombinant":[60],"fusion":[61,123],"cytokine)":[64,278],"a":[66],"collagen-binding":[67],"domain":[68,266],"(CBD)":[69],"derived":[70],"from":[71],"blood":[73,91,157],"protein":[74,109],"von":[75],"Willebrand":[76],"factor":[77],"(VWF)":[78],"A3":[79,265],"domain.":[80],"This":[81],"approach":[82],"harnesses":[83],"exposure":[85],"of":[86,97,128,216,267],"tumor":[87,99,118,182,230,285],"stroma":[88],"collagen":[89],"components":[92],"due":[93],"leakiness":[96],"vasculature.":[100],"Results:":[101],"show":[103],"that":[104,263],"intravenously":[105],"(i.v.)":[106],"administered":[107],"CBD":[108,120],"accumulated":[110],"in":[111,113,155,174,189,213,240,251],"an":[114,227],"orthotopic":[115,228],"MMTV-PyMT":[116,196],"breast":[117,199,229],"model.":[119],"decreased":[124,151],"toxicity":[127],"aCTLA4+aPD-L1":[130],"combination":[131,232],"therapy":[132],"IL-2.":[134],"CBD-conjugation":[135],"abolished":[138],"T":[139,210,221],"cell":[140],"infiltration":[141],"into":[142],"liver":[144],"eliminated":[146],"hepatotoxicity":[147],"as":[148,150,283],"well":[149],"release":[154],"serum.":[158],"CBD-fusion":[159],"ameliorated":[162],"capillary":[163],"leak":[164],"syndrome":[165],"pulmonary":[167],"edema.":[168],"These":[169],"been":[172],"reported":[173],"clinic.":[176],"CBD-CPI":[177,204],"CBD-IL-2":[179,206],"significantly":[180],"suppressed":[181],"growth":[183],"compared":[184,293],"their":[186,295],"unmodified":[187,257],"forms":[188],"B16F10":[190],"melanoma,":[191],"CT26":[192],"colon":[193],"carcinoma":[194],"slow":[197],"growing":[198],"cancer":[200],"models,":[201],"increased":[207],"tumor-infiltrating":[208],"CD8+":[209],"cells;":[211],"increases":[212],"ratio":[215],"effector":[217],"CD8+T":[218],"cells":[219,223],"regulatory":[222],"were":[224],"observed.":[225],"In":[226],"model,":[231],"treatment":[233],"eradicated":[238],"9/13":[241],"animals":[242,254],"CBD-modified":[245],"drugs,":[246],"whereas":[247],"it":[248],"did":[249],"so":[250],"only":[252],"1/13":[253],"drugs.":[258],"Conclusions:":[259],"Our":[260],"data":[261],"suggest":[262],"VWF":[268],"can":[269],"be":[270],"used":[271],"engineer":[273],"immunotherapies":[274],"(e.g.":[275],"high":[280],"translational":[281],"promise":[282],"systemically-administered":[284],"drugs":[287],"improved":[289],"safety":[290],"native":[296],"forms.":[297]},"counts_by_year":[],"updated_date":"2026-08-21T09:56:20.448147","created_date":"2019-06-07T00:00:00"}